Trials / Completed
CompletedNCT04242238
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.
Conditions
- Sarcoma
- Advanced Sarcoma
- High Grade Sarcoma
- Leiomyosarcoma
- Undifferentiated Pleomorphic Sarcoma
- Myxofibrosarcoma
- Dedifferentiated Liposarcoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DCC-3014 | DCC-3014 will be administered in pill form. Start Day 1 on first cycle and continue with dosing of DCC-3014. |
| DRUG | Avelumab | Start Day 1 on first cycle with further infusions of avelumab every 14 days |
Timeline
- Start date
- 2020-01-22
- Primary completion
- 2025-08-26
- Completion
- 2025-08-26
- First posted
- 2020-01-27
- Last updated
- 2025-08-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04242238. Inclusion in this directory is not an endorsement.